News

Who We Are
01.09.2017

HMR starts trial of potential treatment for major symptoms of Alzheimer’s disease

Heptares announced in a press release today that the first subject has been dosed in this ‘phase 1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer’s disease.’ ‘The compound stimulates M4 receptor activity in the brain with high selectivity, and offers the possibility for an improved safety profile over previous muscarinic receptor agonists, which have been associated with adverse effects elsewhere in the body leading to safety and tolerability issues.’


Back to list
National Training Awards ISO 9001 certified LSE Elite A proud member of UK BioIndustry Association one nucleus
certificate